http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1429789-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_886a6eed19ee9de30a2640e774181b7f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 |
| filingDate | 2002-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ee8237a41ff22d0b7eedbd2c60065bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a53b5931b45427f0f2cd45b4948de8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0653afe0f1ae443b5a958f86d9e44538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a807604944dc0f8c128767472f03de3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29c9ff668b6da6f4db9e9fcc4c7eab12 |
| publicationDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1429789-B1 |
| titleOfInvention | Anti-infectious carbohydrates |
| abstract | Neutral, linear or branched oligosaccharides (I), having a structure based on galactose, glucose and N-acetylated galactosamine and/or glucosamine moieties, are used for reducing or inhibiting the invasion and infection of mammalian cells by pathogens and for combating diseases caused by the pathogens. The use of neutral, linear or branched oligosaccharides (I) is claimed for reducing or inhibiting the invasion and infection of mammalian cells by pathogens and for combating diseases caused by the pathogens, where (I) comprises: (a) a base unit of formula R-(Gal(R)-HexNAc)-Gal(R)-Glc; (b) 0-19 further units of formula R-(Gal(R)-HexNAc)-, directly or indirectly linked to the base units; and (c) a terminal (Gal-HexNAc)-unit. Gal : galactose unit Glc : glucose unit; HexNAc : N-acetylated galactosamine (GalNAc) or N-acetylated glucosamine (GlcNAc) unit; R : deoxyhexose residue, beta 1-3 or beta 1-6 glycosidically bonded to the HexNAc moiety of the adjacent (Gal-HexNAc) unit (b) or to the galactose moiety of a terminal (Gal-HexNAc) unit (c); or is absent; a terminal unit (c), to which at least one deoxyhexose unit R is bonded, may carry further deoxyhexose residues. Independent claims are also included for the following: (i) nutritional, dietetic or pharmaceutical compositions (other than human milk), containing (I), conventional additives (such as diluents, humectants, thickeners, flavorings, sweeteners and/or carriers) and optionally other active agents; and (ii) a corresponding treatment method, involving administration of (I) or compositions as in (i) to humans or animals. ACTIVITY : Antibacterial; Virucide. MECHANISM OF ACTION : Blocking or modifying cell surface receptors; inhibiting adhesions of pathogens to cell surfaces. |
| priorityDate | 2001-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.